Skip to content

FFA-Induced Hypertension and Endothelial Dysfunction

Free Fatty Acids-Induced Hypertension and Endothelial Dysfunction in Obese Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00589888
Enrollment
13
Registered
2008-01-10
Start date
2006-08-31
Completion date
2008-08-31
Last updated
2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction, Hypertension

Keywords

hypertension, metabolic syndrome, vascular reactivity, Elevated blood pressure, lipid toxicity

Brief summary

The study is a prospective open label study to examine the effects of oral and intravenous fat load on blood pressure, endothelial function, sympathetic activity, and oxidative stress in obese healthy subjects. Subjects will receive either 8-hour of intravenous or oral fat loads in either low or high doses or normal saline in random order. Blood samples are drawn and vitals are measured before and after the infusions. Endothelial function and plasma glucose and lipid levels are measured to study the effects.

Detailed description

Insulin resistance has been implicated as the central mechanism in the development of several cardiovascular risk factors including hypertension, diabetes, lipid disorders, and coagulation disorders. Recent evidence suggests that increased levels of a circulation fat (free fatty acids or FFAs) are a leading candidate causing insulin resistance. Our preliminary studies in indicate that, in addition to insulin resistance, the infusion of Intralipid and heparin to increase FFAs resulted in a significant rise in systolic and diastolic blood pressure, impaired endothelial (vascular) function, and increased inflammatory markers in obese African Americans with and without diabetes. The effects of FFA on insulin action are well established; however, the blood pressure and vascular effects of FFAs infusion in obese subjects have not been fully investigated. We hypothesize that observed changes in blood pressure are the result of acute endothelial dysfunction, and/or increased activation of the autonomic nervous system. No previous studies have attempted to determine a dose response effect of increasing FFA on blood pressure. In addition, it is not know if increased FFAs by repeated oral fat load results in similar blood pressure than intravenous lipid infusion. Accordingly, we propose: 1) a systematic evaluation of the effects of increasing FFA levels on blood pressure and endothelial (vascular) function, and 2) determine the effects of comparable increases in FFA concentration via intravenous infusion of Intralipid or by repeated oral fat load on blood pressure, insulin resistance and endothelial dysfunction in obese subjects. A group of obese normotensive subjects will be admitted to the Grady Clinical Research Center or to the Outpatient Research Unit in the Grady Diabetes Clinic on five occasions. In four of these admissions, research subjects will receive an 8-hour intravenous infusion, in random order, of increasing Intralipid concentration (10 ml, 20 ml, 40 ml per hour) or normal saline (40 ml per hour). During the final admission, research subjects will receive an oral liquid fat diet every 2 hours for 8-hours. The effect of increased FFAs on blood pressure and endothelial (vascular) function via intravenous infusion and via oral fat load therapy will be assessed.

Interventions

DRUGIntralipid 20% @ 20cc/hour

In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting

DRUGIntralipid 20%@ 40cc/hour

In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.

DRUGNormal Saline

In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.

DIETARY_SUPPLEMENT32-gram oral fat load

In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.

DIETARY_SUPPLEMENT64-gram oral fat load

In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.

Sponsors

American Heart Association
CollaboratorOTHER
Emory University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Males or females between the ages of 18 and 65 years. * Definition: obese = BMI ≥ 30 kg/m2 * Blood pressure \< 140/80 mm Hg and no prior history of hypertension

Exclusion criteria

* History of hypertension or previous history of antihypertensive drug therapy. * Current tobacco use * Fasting triglyceride levels \> 250 mg/dL during the stabilization period. * Liver disease (ALT 2.5x \> upper limit of normal), or other significant medical or surgical illness, including myocardial ischemia, congestive heart failure, liver failure, and infectious processes. * Serum creatinine ≥1.5 mg/dL for males, or ≥ 1.4 mg/dL for females. * History of drug or alcohol abuse within the last 5 years. * Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. * Female subjects are pregnant or breast feeding at time of enrollment into the study.

Design outcomes

Primary

MeasureTime frameDescription
Changes in Systolic Blood Pressure From Baseline to After Completing an Oral 64-gram Fat Load in Obese Normotensive Subjectsat the end of the 8 hoursTo study the effects of high dose oral fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at end of the fat load. The BP from the admission are compared to BP after the fat load. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.
Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects.Baseline and at the end of the 8-hoursTo study the effects of high dose oral fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at end of the fat load. The BP from the admission are compared to BP after the fat load. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.
Change in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 20cc/hr Infusion in Obese Normotensive Subjects.Baseline and at the end of the 8-hoursTo study the effects of low dose intravenous (IV) fat infusion on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at every 2 hours till the end of infusion. The BP from the admission are compared to BP after the infusion.A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.
Changes in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 40cc/hr Infusion in Obese Normotensive SubjectsBaseline and at the end of the 8-hoursTo study the effects of high dose intravenous (IV) fat infusion on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at every 2 hours till the end of infusion. The BP from the admission are compared to BP after the infusion. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.
Change in Systolic Blood Pressure From Baseline to After Completing an Oral 32-gram Fat Load in Obese Normotensive Subjects.Baseline and at the end of the 8-hoursTo study the effects of oral low dose fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position.The Blood pressure was measured at admission and at end of the fat load. The BP from the admission are compared to BP after the fat load. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.

Secondary

MeasureTime frameDescription
Change in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy SubjectsBaseline and at the end of the 8-hoursThe blood glucose level is the amount of glucose present in the blood of humans. Many factors affect a person's blood sugar level. The body's homeostatic mechanism of blood sugar regulation (known as glucose homeostasis), when operating normally, restores the blood sugar level to a narrow range of about 4.4 to 6.1 mmol/L (79 to 110 mg/dL) (as measured by a fasting blood glucose test). The study aims to study the effects of these interventions on blood glucose levels among obese healthy subjects.
Change in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjectsbaseline and after 8 hours after admissionC-peptide is a peptide composed of 31 amino acids. It is released from the pancreatic beta-cells during cleavage of insulin from proinsulin. It is mainly excreted by the kidney, and its half-life is 3-4 times longer than that of insulin. The reference range of C-peptide is 0. 8-3 ng/ml. The C-peptide test is a tool to monitor and treat diabetes. It shows how well your body makes insulin, which moves sugar (or glucose) from your blood into your cells.
Change in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese SubjectsBaseline and at the end of the 8-hoursInsulin is an anabolic hormone that promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis of skeletal muscle and fat tissue through the tyrosine kinase receptor pathway. In addition, insulin is the most important factor in the regulation of plasma glucose homeostasis, as it counteracts glucagon and other catabolic hormones like epinephrine, glucocorticoid, and growth hormone. Normal fasting insulin levels is \< 25 milli-International unit/litre
Change in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.Baseline and at the end of the 8-hoursEndothelium-dependent brachial artery dilatation was assessed as a measurement of endothelial function using established methodology. Briefly, ultrasound images of the brachial artery were obtained at baseline under standardized conditions and 60 s after induction of reactive hyperemia by 5-min cuff occlusion of the forearm. Image landmarks as well as surface markers were utilized to ensure anatomic consistency between serial imaging studies. All images were digitized online, and arterial diameters were measured with customized software by individuals blinded to the clinical and laboratory status of the subjects. Flow-mediated dilatation (FMD) was expressed as the percentage increase in diameter from baseline. It is measured in percentage.

Countries

United States

Participant flow

Pre-assignment details

For this study, same 13 subjects were admitted to the General Clinical Research Center at Grady Memorial Hospital in random order on five different occasions to receive either 8-h iv or oral fat loads in either low or high doses or normal saline.

Participants by arm

ArmCount
All Study Participants
All participants received all 5 arms in random order: 1. 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours 2. Intralipid 20% @ 20cc/hr for 8 hours 3. Intralipid 20% @ 40cc/Hr for 8 hours 4. 32-gram Oral Fat Load every 2 hours for 8 hours. 5. 64-gram Oral Fat Load every 2 hours for 8 hours.
13
Total13

Baseline characteristics

CharacteristicAll Study Participants
Age, Continuous32.2 years
STANDARD_DEVIATION 9.8
Baseline Flow-mediated dilatation (FMD) of Brachial Artery9.4 percentage
STANDARD_DEVIATION 2.7
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
12 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
1 Participants
Sex: Female, Male
Female
9 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
deaths
Total, all-cause mortality
0 / 130 / 130 / 130 / 130 / 13
other
Total, other adverse events
0 / 131 / 131 / 130 / 131 / 13
serious
Total, serious adverse events
0 / 130 / 130 / 130 / 130 / 13

Outcome results

Primary

Change in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 20cc/hr Infusion in Obese Normotensive Subjects.

To study the effects of low dose intravenous (IV) fat infusion on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at every 2 hours till the end of infusion. The BP from the admission are compared to BP after the infusion.A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.

Time frame: Baseline and at the end of the 8-hours

ArmMeasureValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChange in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 20cc/hr Infusion in Obese Normotensive Subjects.14 mmHgStandard Deviation 10
Primary

Change in Systolic Blood Pressure From Baseline to After Completing an Oral 32-gram Fat Load in Obese Normotensive Subjects.

To study the effects of oral low dose fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position.The Blood pressure was measured at admission and at end of the fat load. The BP from the admission are compared to BP after the fat load. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.

Time frame: Baseline and at the end of the 8-hours

ArmMeasureValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChange in Systolic Blood Pressure From Baseline to After Completing an Oral 32-gram Fat Load in Obese Normotensive Subjects.13 mmHgStandard Deviation 17
Primary

Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects.

To study the effects of high dose oral fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at end of the fat load. The BP from the admission are compared to BP after the fat load. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.

Time frame: Baseline and at the end of the 8-hours

ArmMeasureValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChange in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects.13 mmHgStandard Deviation 17
Primary

Changes in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 40cc/hr Infusion in Obese Normotensive Subjects

To study the effects of high dose intravenous (IV) fat infusion on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at every 2 hours till the end of infusion. The BP from the admission are compared to BP after the infusion. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.

Time frame: Baseline and at the end of the 8-hours

ArmMeasureValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChanges in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 40cc/hr Infusion in Obese Normotensive Subjects12 mmHgStandard Deviation 9
Primary

Changes in Systolic Blood Pressure From Baseline to After Completing an Oral 64-gram Fat Load in Obese Normotensive Subjects

To study the effects of high dose oral fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion. Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position. The Blood pressure was measured at admission and at end of the fat load. The BP from the admission are compared to BP after the fat load. A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg. A level above 140 mmHg is considered hypertension.

Time frame: at the end of the 8 hours

ArmMeasureValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChanges in Systolic Blood Pressure From Baseline to After Completing an Oral 64-gram Fat Load in Obese Normotensive Subjects11 mmHgStandard Deviation 11
Secondary

Change in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy Subjects

The blood glucose level is the amount of glucose present in the blood of humans. Many factors affect a person's blood sugar level. The body's homeostatic mechanism of blood sugar regulation (known as glucose homeostasis), when operating normally, restores the blood sugar level to a narrow range of about 4.4 to 6.1 mmol/L (79 to 110 mg/dL) (as measured by a fasting blood glucose test). The study aims to study the effects of these interventions on blood glucose levels among obese healthy subjects.

Time frame: Baseline and at the end of the 8-hours

ArmMeasureGroupValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy SubjectsAfter intervention blood glucose level84.2 mg/dLStandard Deviation 5.7
Normal Saline @ 40cc/HourChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy Subjectsbaseline blood glucose level93.9 mg/dLStandard Deviation 4.4
Intralipid 20% @ 40cc/HourChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy SubjectsAfter intervention blood glucose level86.1 mg/dLStandard Deviation 8.1
Intralipid 20% @ 40cc/HourChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy Subjectsbaseline blood glucose level92.3 mg/dLStandard Deviation 9.2
Normal Saline Infusion @ 40cc/HourChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy Subjectsbaseline blood glucose level91.5 mg/dLStandard Deviation 8.5
Normal Saline Infusion @ 40cc/HourChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy SubjectsAfter intervention blood glucose level81.7 mg/dLStandard Deviation 7.2
32-gram Oral Fat LoadChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy Subjectsbaseline blood glucose level91.5 mg/dLStandard Deviation 6.4
32-gram Oral Fat LoadChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy SubjectsAfter intervention blood glucose level87.8 mg/dLStandard Deviation 7.8
64-gram Oral Fat LoadChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy SubjectsAfter intervention blood glucose level87.8 mg/dLStandard Deviation 10.3
64-gram Oral Fat LoadChange in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy Subjectsbaseline blood glucose level87.1 mg/dLStandard Deviation 4
Secondary

Change in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese Subjects

Insulin is an anabolic hormone that promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis of skeletal muscle and fat tissue through the tyrosine kinase receptor pathway. In addition, insulin is the most important factor in the regulation of plasma glucose homeostasis, as it counteracts glucagon and other catabolic hormones like epinephrine, glucocorticoid, and growth hormone. Normal fasting insulin levels is \< 25 milli-International unit/litre

Time frame: Baseline and at the end of the 8-hours

Population: the same 13 subjects underwent different interventions in random order on different occasions

ArmMeasureGroupValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese Subjectsbaseline blood insulin8.5 milli-International unit /LitreStandard Deviation 7.1
Normal Saline @ 40cc/HourChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese SubjectsAfter intervention blood insulin level8.6 milli-International unit /LitreStandard Deviation 5.7
Intralipid 20% @ 40cc/HourChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese Subjectsbaseline blood insulin9.2 milli-International unit /LitreStandard Deviation 4.5
Intralipid 20% @ 40cc/HourChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese SubjectsAfter intervention blood insulin level9.1 milli-International unit /LitreStandard Deviation 4.4
Normal Saline Infusion @ 40cc/HourChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese Subjectsbaseline blood insulin8.8 milli-International unit /LitreStandard Deviation 5
Normal Saline Infusion @ 40cc/HourChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese SubjectsAfter intervention blood insulin level5.2 milli-International unit /LitreStandard Deviation 3.5
32-gram Oral Fat LoadChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese SubjectsAfter intervention blood insulin level11.5 milli-International unit /LitreStandard Deviation 6
32-gram Oral Fat LoadChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese Subjectsbaseline blood insulin7.8 milli-International unit /LitreStandard Deviation 4.1
64-gram Oral Fat LoadChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese Subjectsbaseline blood insulin9.1 milli-International unit /LitreStandard Deviation 2.7
64-gram Oral Fat LoadChange in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese SubjectsAfter intervention blood insulin level12.9 milli-International unit /LitreStandard Deviation 9.4
Secondary

Change in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjects

C-peptide is a peptide composed of 31 amino acids. It is released from the pancreatic beta-cells during cleavage of insulin from proinsulin. It is mainly excreted by the kidney, and its half-life is 3-4 times longer than that of insulin. The reference range of C-peptide is 0. 8-3 ng/ml. The C-peptide test is a tool to monitor and treat diabetes. It shows how well your body makes insulin, which moves sugar (or glucose) from your blood into your cells.

Time frame: baseline and after 8 hours after admission

ArmMeasureGroupValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjectsbaseline C- Peptide1.64 ng/mlStandard Deviation 0.84
Normal Saline @ 40cc/HourChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese SubjectsAfter intervention C- Peptide level2.1 ng/mlStandard Deviation 1.08
Intralipid 20% @ 40cc/HourChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjectsbaseline C- Peptide2.06 ng/mlStandard Deviation 0.69
Intralipid 20% @ 40cc/HourChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese SubjectsAfter intervention C- Peptide level2.05 ng/mlStandard Deviation 0.62
Normal Saline Infusion @ 40cc/HourChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjectsbaseline C- Peptide1.95 ng/mlStandard Deviation 0.87
Normal Saline Infusion @ 40cc/HourChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese SubjectsAfter intervention C- Peptide level1.49 ng/mlStandard Deviation 0.63
32-gram Oral Fat LoadChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese SubjectsAfter intervention C- Peptide level2.51 ng/mlStandard Deviation 0.78
32-gram Oral Fat LoadChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjectsbaseline C- Peptide2.02 ng/mlStandard Deviation 0.59
64-gram Oral Fat LoadChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjectsbaseline C- Peptide2.5 ng/mlStandard Deviation 0.41
64-gram Oral Fat LoadChange in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese SubjectsAfter intervention C- Peptide level2.49 ng/mlStandard Deviation 1.03
Secondary

Change in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.

Endothelium-dependent brachial artery dilatation was assessed as a measurement of endothelial function using established methodology. Briefly, ultrasound images of the brachial artery were obtained at baseline under standardized conditions and 60 s after induction of reactive hyperemia by 5-min cuff occlusion of the forearm. Image landmarks as well as surface markers were utilized to ensure anatomic consistency between serial imaging studies. All images were digitized online, and arterial diameters were measured with customized software by individuals blinded to the clinical and laboratory status of the subjects. Flow-mediated dilatation (FMD) was expressed as the percentage increase in diameter from baseline. It is measured in percentage.

Time frame: Baseline and at the end of the 8-hours

ArmMeasureValue (MEAN)Dispersion
Normal Saline @ 40cc/HourChange in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.3.8 percentage of FMDStandard Deviation 2.1
Intralipid 20% @ 40cc/HourChange in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.4.1 percentage of FMDStandard Deviation 3.1
Normal Saline Infusion @ 40cc/HourChange in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.0.3 percentage of FMDStandard Deviation 0.1
32-gram Oral Fat LoadChange in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.3.8 percentage of FMDStandard Deviation 1.8
64-gram Oral Fat LoadChange in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.5 percentage of FMDStandard Deviation 2.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026